Please assess the completion status of the following clinical trial:

Trial Title: Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets protocol-specified criteria for qualification and contraception~* Is willing and able to comply with any restrictions related food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban-based Regimen (Type: EXPERIMENTAL): Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the end of treatment. Dosing must follow the locally approved label.
- VKA-based Regimen (Type: ACTIVE_COMPARATOR): VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.

Based on this trial design, predict the completion outcome and termination type (if applicable).